Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer

Trial Profile

Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 09 May 2016 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top